

**NSABP Protocol B-23: Characteristics of Patients  
for whom Pathology Material is Available for Study**

	<b>CMF + PLAC</b>		<b>CMF + TAM</b>		<b>AC + PLAC</b>		<b>AC + TAM</b>		<b>All</b>	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
<b>Age</b>										
≤49	129	(54.9)	111	(51.2)	132	(55.5)	127	(59.3)	499	(55.2)
50-59	68	(28.9)	64	(29.5)	66	(27.7)	55	(25.7)	253	(28.0)
≥60	38	(16.2)	42	(19.4)	40	(16.8)	32	(15.0)	152	(16.8)
<b>Race</b>										
White	193	(82.1)	172	(79.3)	187	(78.6)	168	(78.5)	720	(79.6)
Black	34	(14.5)	30	(13.8)	39	(16.4)	34	(15.9)	137	(15.2)
Other	8	(3.4)	13	(6.0)	9	(3.8)	6	(2.8)	36	(4.0)
Unknown	0	(0.0)	2	(0.9)	3	(1.3)	6	(2.8)	11	(1.2)
<b>Clinical Tumor Size (cm)</b>										
≤2.0	134	(57.0)	130	(59.9)	143	(60.1)	104	(48.6)	511	(56.5)
2.1-4.0	92	(39.1)	75	(34.6)	85	(35.7)	89	(41.6)	341	(37.7)
≥4.1	6	(2.6)	9	(4.1)	8	(3.4)	13	(6.1)	36	(4.0)
Unknown	3	(1.3)	3	(1.4)	2	(0.8)	8	(3.7)	16	(1.8)
<b>Type of Surgery</b>										
Lumpectomy + AD	139	(59.1)	119	(54.8)	128	(53.8)	117	(54.7)	503	(55.6)
Modified Radical	96	(40.9)	98	(45.2)	110	(46.2)	97	(45.3)	401	(44.4)
<b>Estrogen Receptor</b>										
0-9 fmol	227	(96.6)	214	(98.6)	231	(97.1)	211	(98.6)	883	(97.7)
≥10	8	(3.4)	3	(1.4)	7	(2.9)	3	(1.4)	21	(2.3)
<b>Progesterone Receptor</b>										
0-9 fmol	201	(85.5)	197	(90.8)	213	(89.5)	187	(87.4)	798	(88.3)
≥10	34	(14.5)	20	(9.2)	25	(10.5)	27	(12.6)	106	(11.7)
<b>Disease-free Survival</b>										
Event-free	179	(76.2)	157	(72.4)	164	(68.9)	148	(69.2)	648	(71.7)
Experienced an Event	56	(23.8)	60	(27.6)	74	(31.1)	66	(30.8)	256	(28.3)
Total Person Months of Follow-up for Events	24,834.9		21,646.3		23,810.0		21,976.2		92,267.4	
<b>Overall Survival</b>										
Alive	206	(87.7)	179	(82.5)	195	(81.9)	176	(82.2)	756	(83.6)
Dead	29	(12.3)	38	(17.5)	43	(18.1)	38	(17.8)	148	(16.4)
Total Person Months of Follow-up for Deaths	26,442.4		23,591.0		26,189.2		24,238.5		100,461.1	
<b>All</b>	235	(100.0)	217	(100.0)	238	(100.0)	214	(100.0)	904	(100.0)